Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 15;23(14):3610-3618.
doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

Min Yuen Teo  1 , Richard M Bambury  2 , Emily C Zabor  3 , Emmet Jordan  1 , Hikmat Al-Ahmadie  4 , Mariel E Boyd  1 , Nancy Bouvier  5 , Stephanie A Mullane  6 , Eugene K Cha  7 , Nitin Roper  8 , Irina Ostrovnaya  3 , David M Hyman  9 , Bernard H Bochner  7 , Maria E Arcila  4 , David B Solit  1 , Michael F Berger  5 , Dean F Bajorin  1 , Joaquim Bellmunt  6 , Gopakumar Iyer  1 , Jonathan E Rosenberg  10
Affiliations

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

Min Yuen Teo et al. Clin Cancer Res. .

Abstract

Purpose: Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in DNA damage response and repair (DDR) genes are associated with improved sensitivity to platinum-based chemotherapy.Experimental Design: Patients with diagnosis of locally advanced and metastatic urothelial carcinoma treated with platinum-based chemotherapy who had exon sequencing with the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay were identified. Patients were dichotomized based on the presence/absence of alterations in a panel of 34 DDR genes. DDR alteration status was correlated with clinical outcomes and disease features.Results: One hundred patients were identified, of which 47 harbored alterations in DDR genes. Patients with DDR alterations had improved progression-free survival (9.3 vs. 6.0 months, log-rank P = 0.007) and overall survival (23.7 vs. 13.0 months, log-rank P = 0.006). DDR alterations were also associated with higher number mutations and copy-number alterations. A trend toward positive correlation between DDR status and nodal metastases and inverse correlation with visceral metastases were observed. Different DDR pathways also suggested variable impact on clinical outcomes.Conclusions: Somatic DDR alteration is associated with improved clinical outcomes in platinum-treated patients with advanced urothelial carcinoma. Once validated, it can improve patient selection for clinical practice and future study enrollment. Clin Cancer Res; 23(14); 3610-8. ©2017 AACR.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest disclosures: Jonathan E. Rosenberg has a patent issued for ERCC2 chemotherapy sensitivity. The remaining authors made no disclosures.

Figures

Figure 1
Figure 1
The association between DDR (DNA damage response and repair) gene alteration status and (A) progression-free (PFS) and (B) overall survival (OS). DDRalt: altered DDR; DDRwt: wild type DDR.
Figure 2
Figure 2
Frequency of metastasis by site based on number of DDR alterations: (A) visceral metastasis, (B) nodal metastasis only (no visceral involvement), (C) any hepatic involvement, (D) any pulmonary involvement, (E) any osseous involvement and (F) any nodal involvement.
Figure 3
Figure 3
Influence of alterations in individual DDR pathways or components on (A) Progression-free survival and (B) overall survival.
See this image and copyright information in PMC

Comment in

References

    1. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8. - PubMed
    1. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) Ann Oncol. 2013;24:1011–7. - PubMed
    1. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191–9. - PMC - PubMed
    1. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003;97:2180–6. - PubMed
    1. Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol. 2001;12:947–52. - PubMed

MeSH terms